Shares of Vertex Pharmaceuticals VRTX fell 1.1% in after-market trading after the company reported Q4 results.
Quarterly Results
Earnings per share rose 47.65% year over year to $2.51, which missed the estimate of $2.59.
Revenue of $1,628,000,000 rose by 29.51% year over year, which beat the estimate of $1,580,000,000.
Guidance
Earnings guidance hasn't been issued by the company for now.
Revenue guidance hasn't been issued by the company for now.
Conference Call Details
Date: Feb 01, 2021
Time: 04:30 PM
ET Webcast URL: https://event.webcasts.com/starthere.jsp?ei=1422591&tp_key=ff479c3073
Technicals
52-week high: $306.08
52-week low: $197.47
Price action over last quarter: Up 8.71%
Company Overview
Vertex Pharmaceuticals discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex's pipeline also includes therapies for cancer, pain, inflammatory diseases, influenza, and other rare diseases.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.